Skip to content

Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products

Drug Utilization Study of Trends in Prescriptions for Class REMS ER/LA Opioids and Comparator Products; Evaluation of Drug Utilization Patterns

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02925806
Enrollment
5575834
Registered
2016-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2016-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Abuse, Narcotic Abuse, Opiate Addiction, Opioid Related Disorders

Brief summary

A drug utilization study will be performed to describe trends in the number of prescriptions and patients for class REMS ER/LA opioids and comparator products.

Detailed description

A drug utilization study will be performed to describe trends in the number of prescriptions and patients for class REMS ER/LA opioids and comparator products. The specific objectives of the Drug Utilization Study are: 1. To estimate trends by month in the number of prescriptions for a one-year period before, and each month after, the implementation of the REMS 2. To compare average number of prescriptions per 3 month (quarter) period in the 2 years before as compared to the same measure during Implementation and the Active Period 3. To evaluate change by patient characteristics (age group, gender, pay type, prescriber specialty) 4. To compare the trends in prescribing, both number of prescriptions and patients, by prescriber specialty These trends and changes over time will be estimated for the following groups of opioids: * ER/LA opioids included in the class REMS * Comparator products/classes * Immediate release (IR) opioids * Celecoxib * Benzodiazepines 5. To show switches (absolute and rates of switching) from ER/LA opioids to comparator analgesics (IR opioids or celecoxib) with introduction of REMS

Interventions

Sponsors

ER/LA Opioid REMS Program Companies (RPC)
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 100 Years

Inclusion criteria

* Subjects filling a prescription for a product of interest during the specified time period will be included.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Number of opioid prescriptions filledMonthly over 54 months
Compare average number of prescriptions per time period in the 2 years before as compared to the same measure in implementation and active periodsPre REMS Implementation (July 10-June 12)
Compare trends in prescribing, both number of prescriptions and patients, by prescriber specialtyPre REMS Implementation (July 10-June 12)
Number and Rate of Switches from ER/ LA opioids to comparator analgesics with introduction of REMSMonthly over 54 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026